Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial.

BreastJul 19, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)Open access

Mengxue Qiu, Hui Dai, Tao Zhu et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase III multicentre randomized controlled trial compared minimal incision-assisted endoscopic breast-conserving surgery (M-E-BCS) with conventional open breast-conserving surgery (C-O-BCS) in early-stage breast cancer patients. M-E-BCS resulted in significantly higher SCAR-Q scores (79.9 vs. 61.4, P < 0.001) at 18 months, indicating better aesthetic outcomes and quality of life.

Key findings

  • M-E-BCS achieved a SCAR-Q score of 79.9 ± 9.5 compared to 61.4 ± 17.4 for C-O-BCS (P < 0.001).
  • Patients reported greater improvement in BREAST-Q breast satisfaction with M-E-BCS (17.7 ± 18.2 vs. 5.4 ± 21.5, P < 0.001).
  • The physician assessment showed an 'excellent' rate of 86.5% for M-E-BCS versus 57.9% for C-O-BCS.

Why it matters

The findings suggest that M-E-BCS offers superior aesthetic and quality of life outcomes for patients undergoing breast-conserving surgery, which may influence surgical decision-making and patient satisfaction.

Source

PubMed · PMID 42497645Free full text on PubMed Central

Published in Breast. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.